The generation of an anti-malarial vaccine that produces broad, potent, and durable
responses is highly desirable to control the burden of Plasmodium falciparum disease …

Potent and durable vaccine responses will be required for control of malaria caused by
Plasmodium falciparum (Pf). RTS, S/AS01 is the first, and to date, the only vaccine that has …

Malaria affects∼ ¼ billion people globally and requires the development of additional tools
to aid in elimination efforts. The recently approved RTS, S/AS01 vaccine represents a …

Background Plasmodium falciparum circumsporozoite protein (CSP) is a leading malaria
vaccine candidate antigen, known to elicit protective antibody responses in humans (RTS, S …

Efficacy data on two malaria vaccines, RTS, S and R21, targeting Plasmodium falciparum
circumsporozoite protein (Pf CSP), are encouraging. Efficacy may be improved by induction …

Background: Plasmodium falciparum circumsporozoite protein (CSP) is the target of multiple
vaccines in development. New promising monoclonal antibodies target the CSP junctional …

Introduction A safe and effective vaccine will likely be necessary for the control or
eradication of malaria which kills 400,000 annually. Our most advanced vaccine candidate …

The induction of protective humoral immune responses against sporozoite surface proteins
of the human parasite Plasmodium falciparum (Pf) is a prime goal in the development of a …

Introduction Pre-erythrocytic malaria vaccines hold the promise of inducing sterile protection
thereby preventing the morbidity and mortality associated with Plasmodium infection. The …

Plasmodium falciparum malaria, a mosquito-borne, unicellular parasitic disease, remains a
major health concern, particularly in the sub-Saharan Africa. Despite many attempts to …